Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13

@uranium69

Whenever we look at the fundamentals, decide to invest and hold for longer term more often than not we need to go through this pain.. I had similar problem with couple of other stocks I held, you could have added more in the early twenties or even now to reduce your average cost, unlike other clinical stage pharma here we don't have the risk of capital raise thus those who sold with a view to get back in at a lower price will have to come back sometime during the trial, current month is bit eventful for TRP due to the online pro+ sales, feedback and FDA catch up which will give a clear indication about phase-3